

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

LINC

The logo for LINC (Leipzig Interventional Course) features the letters 'LINC' in a bold, blue, sans-serif font. Behind the letters is a stylized graphic consisting of two overlapping, curved, brushstroke-like shapes in shades of blue and grey, suggesting a dynamic or medical theme.

Andrew Holden

Page 1/9

Monday, January 25, 2021

LINC STUDIO

09:00 – 09:15 **LINC Studio – Covered stents in clinical practice: case review and discussion round**

MODERATOR:

Dierk Scheinert

GUEST:

Andrej Schmidt

Andrew Holden

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Andrew Holden

Page 2/9

Monday, January 25, 2021

MAIN ARENA 1

11:30 – 12:25	SYMPOSIUM: A new era for vascular access: evidence-based strategies for optimizing AV fistula creation and maintenance supported by Medtronic <i>MODERATOR:</i> Andrew Holden <i>PANEL:</i> Alexandros Mallios Jeffrey Hull Tobias Steinke
11:30 – 11:35	Introduction Andrew Holden
11:35 – 11:40	Panel discussion
11:40 – 11:50	Endovascular or surgical AV access creation: which option for which patient? Alexandros Mallios
11:50 – 11:55	Panel discussion
11:55 – 12:05	Challenges in AV access maintenance: treating the cephalic arch Jeffrey Hull
12:05 – 12:10	Panel discussion
12:10 – 12:20	My AV access maintenance algorithm Tobias Steinke
12:20 – 12:25	Panel discussion and programme conclusions

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Andrew Holden

Page 3/9

Tuesday, January 26, 2021

MAIN ARENA 1

- 11:45 – 12:10** **Pioneering approaches and new data: focus on venous and AV-shunt treatment**
MODERATOR:
Marianne Brodmann
Michael Lichtenberg
PANEL:
Robert Shahverdyan
Tobias Steinke
- 11:45 – 11:50 FIRST TIME DATA RELEASE: The IN.PACT AV access trial: subset outcomes through 12 month
Andrew Holden
- 11:50 – 11:55 The IN.PACT AV access trial – economic outcomes
Robert Lookstein
- 11:55 – 12:00 VIVO clinical study: Zilver Vena stent – 12 month results
Lawrence Hofmann
- 12:00 – 12:05 Data from the ABRE study: clinical patient presentations in iliofemoral venous outflow obstruction – aDVT, PTS, NIVL
Erin Murphy
- 12:05 – 12:10 FIRST TIME DATA RELEASE: Retrospective comparison of surgical AV access fistula creation vs. pAVF creation
Robert Shahverdyan

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for the Leipzig Interventional Course (LINC) features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Andrew Holden

Page 4/9

Wednesday, January 27, 2021

MAIN ARENA 1

- 19:00 – 20:20** **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**
MODERATOR:
Dierk Scheinert
Peter Schneider
PANEL:
Andrew Holden
Marianne Brodmann
Robert Lookstein
- 19:00 – 19:03 Introduction by the moderators
Dierk Scheinert
Peter Schneider
- 19:03 – 19:08 Insights on paclitaxel safety from the femoral-popliteal RCTs
Peter Schneider
- 19:08 – 19:13 Insights on paclitaxel safety from femoral-popliteal real-world data
Eric Secemsky
- 19:13 – 19:21 New insights from the interim safety analysis of the SWEDEPAD study
Joakim Nordanstig
- 19:21 – 19:26 How does the Voyager data help us understand the risks of paclitaxel?
Marc Bonaca
- 19:26 – 19:31 Paclitaxel safety in patients with CLTI
Marianne Brodmann
- 19:31 – 19:36 Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications
Robert Lookstein
- 19:36 – 19:41 New data on paclitaxel in the next couple of years; what should we expect?
Eva Freisinger
- 19:41 – 19:49 Panel discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Andrew Holden

Page 5/9

Wednesday, January 27, 2021

- | | |
|---------------|---|
| 19:49 – 19:54 | Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?
Sahil Parikh |
| 19:54 – 19:59 | Previous experience with limus compounds in the non-coronary arteries; lessons learned
Thomas Zeller |
| 19:59 – 20:04 | New limus delivering devices for above and below knee occlusive disease; when to expect results?
Andrew Holden |
| 20:04 – 20:14 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?
Dierk Scheinert |
| 20:14 – 20:20 | Panel discussion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Andrew Holden

Page 6/9

Thursday, January 28, 2021

MAIN ARENA 1

- 07:00 – 09:00** **Challenges in EVAR: focus on aortic dissections and innovations for aortic arch treatment**
partially supported by Gore & Associates
MODERATOR:
Tilo Kölbel
Andrew Holden
PANEL:
Vicente Riambau
Wei Guo
Vikram Puttaswamy
- 07:00 – 07:25 Live case transmission from Leipzig
Universitätsklinikum Leipzig, Abt. Angiologie - Live case center
- 07:25 – 07:30 Type A aortic dissection – current knowledge gaps
Michael Borger
- 07:30 – 07:35 Open and endovascular surgery after frozen elephant trunk for extensive aortic aneurysms
Michael Jacobs
- 07:35 – 07:40 WeFlow-Arch™: a new modular double inner branch stent graft for endovascular repair of aortic arch pathology
Wei Guo
- 07:40 – 07:45 Off-the-shelf treatment of aortic arch pathologies with Nexus
Michele Antonello
- 07:45 – 07:50 Optimizing TEVAR outcomes in acute and subacute type B aortic dissections, what is the right amount of radial force?
Stefano Fazzini
- 07:50 – 07:55 Tailoring the treatment of fragile aorta with the Valiant Navion covered seal device: my clinical experience in TBAD
Theodoros Kratimenos
- 07:55 – 08:00 Conformability and dissection, is it important?
Joseph Hockley
- 08:00 – 08:05 Identifying at risk patients: who could benefit from TEVAR in uncomplicated type B dissections
Vikram Puttaswamy

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Andrew Holden

Page 7/9

Thursday, January 28, 2021

- | | |
|---------------|--|
| 08:05 – 08:10 | Short-term results of TEVAR in complicated vs. uncomplicated acute type B aortic dissection: a report from the Gore Global Registry for Endovascular Aortic Treatment (GREAT)
Santi Trimarchi |
| 08:10 – 08:15 | Meeting an unmet need: the DISSECT-N trial
Robin Hendricus Heijmen |
| 08:15 – 08:20 | Treatment approaches for the distal landing zone for type B dissection
Andrew Holden |
| 08:20 – 08:25 | Multicentre data on the usage of large covered stents in aortic blisters/PAU instead of an EVAR device
Nikolaos Tsilimparis |
| 08:25 – 08:50 | Live case transmission from Universitätsklinik für Herzchirurgie Leipzig
Universitätsklinik für Herzchirurgie Leipzig - Live case center |
| 08:50 – 09:00 | Q&A, discussion, and conclusion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Andrew Holden

Page 8/9

Friday, January 29, 2021

MAIN ARENA 1

- 07:00 – 09:00** **Novel techniques for treatment of complex BTK disease in CLI**
MODERATOR:
Jos van den Berg
Steven Kum
PANEL:
Roberto Ferraresi
Andrew Holden
Luis Palena
- 07:00 – 07:30 Live case transmission from Beijing
301 General Hospital of PLA, Beijing - Live case center
- 07:30 – 07:35 Tips and tricks for optimal angiographic imaging of BTK and foot arteries
Marco Manzi
- 07:35 – 07:40 Indirect vs. direct revascularization for CLI treatment: best practice in 2021
Roberto Ferraresi
- 07:40 – 07:45 Balloon angioplasty of infrapopliteal arteries: a proposed algorithm for optimal endovascular treatment
Ehrin Armstrong
- 07:45 – 07:50 Is bigger better in BTK arteries? The role luminal gain and how to achieve it?
Steven Kum
- 07:50 – 07:55 The PRELUDE-BTK study: novel serration angioplasty balloon for below-the-knee arteries
Andrew Holden
- 07:55 – 08:25 Live case transmission from Abano Terme
Policlinico Abano Terme - Live case center
- 08:25 – 08:30 Dissection repair in below-the-knee: evidence review and learnings from the TOBA II BTK trial
Michael Lichtenberg
- 08:30 – 08:35 Where do we stand with DCB therapy in BTK arteries?
Francesco Liistro
- 08:35 – 08:40 The drug-coated temporary spur stent system: innovation in drug delivery for treating CLI
Jihad Mustapha

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Andrew Holden

Page 9/9

Friday, January 29, 2021

- | | |
|---------------|--|
| 08:40 – 08:45 | XTOSI 12 month results: Xtreme Touch-Neo (MagicTouch PTA) Sirolimus coated balloon for peripheral arterial disease
Edward Choke |
| 08:45 – 08:50 | BTK interventions in 2025: what is going to help to make BTK procedures more effective?
William Gray |
| 08:50 – 09:00 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.